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A hallmark of many ciliopathies are renal cysts, ultimately
disrupting kidney architecture and resulting in end-stage
renal disease as the most common cause of mortality. Yet
despite being the largest demand for renal replacement
therapy (ie. dialysis, kidney transplantation) in young
patients, the exact etiology of nephronophthisis (NPHP)
and polycystic kidney disease is still largely unknown. Many
gene products associated with NPHP and related disorders
do not directly affect cilia, but appear to be important in
tubular architecture, lumen formation, and polarized exocy-
tosis. Personalized therapy to delay disease progression is
beginning to explore gene replacement therapy, through
use -for example- of induced pluripotent stem cells (iPSCs).
For patients with nonsense mutations in ciliopathy genes,
read-through drugs such as PTC124 and modified amino-
glycosides might hold future promise. Furthermore, several
drug screens in cell-based, zebrafish, and murine models
have suggested new pathways preserving kidney function.
Although much of this work has yet to be validated in
human patients, this overview will discuss the approaches
currently being employed in the context of improving cilio-
pathy treatment options.
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